Dyne Therapeutics Inc.. (10/1/19). "Press Release: Dyne Therapeutics Announces Appointment of Joshua Brumm as President and Chief Executive Officer". Waltham, MA.

	Organisation	Dyne Therapeutics Inc.
	Organisation 2	Kaleido Biosciences Inc. (Nasdaq: KLDO)
	Product	FORCE™ platform of antibody conjugates
	Product 2	drug development
	Person	Rhodes, Jason P. (Atlas Venture 2014– Partner formerly Epizyme + Alnylam + Fidelity Biosciences)
	Person 2	Subramanian, Romesh (201904 CEO before RaNa Therapeutics + Alexion Pharmaceuticals)

Industry veteran brings extensive experience leading biotech companies through periods of growth

Dyne Therapeutics, a biotechnology company pioneering targeted therapies for patients with serious muscle diseases, today announced the appointment of Joshua Brumm as President and Chief Executive Officer.

“Josh brings extraordinary skills and experience to further our mission of creating life-transforming therapies for patients with serious muscle diseases,” said Jason Rhodes, partner with Atlas Venture and Dyne founder and executive chairman of the board of directors. “This positions us strongly to pursue the next phase of growth and product development, and we are thrilled to have him joining us.”

“Dyne’s FORCE therapeutic platform achieves a unique combination of tissue-specific delivery, high potency and tolerability to enable a broad product pipeline,” said Joshua Brumm. “I look forward to working closely with the board and talented team at Dyne to maximize the potential of our platform by advancing our pipeline and exploring new partnerships.”

“On behalf of everyone here, I am excited to welcome Josh,” said Romesh Subramanian, Dyne founder and chief scientific officer. “We look forward to working together to realize the therapeutic power of oligonucleotides for patients with rare muscle diseases and fulfilling Dyne’s mission.”

Prior to joining Dyne, Mr. Brumm served as chief operating officer and chief financial officer of Kaleido Biosciences, where he led the company’s financings including its initial public offering and helped bring the lead program into Phase 2 development. Prior to joining Kaleido, Mr. Brumm was COO and CFO at Versartis, where he oversaw the company’s financial strategy including the successful completion of its IPO, played an integral role in product strategy, and helped negotiate the company’s first product partnership. His previous roles include serving as executive vice president of finance and principal financial officer at Pharmacyclics; CFO at ZELTIQ Aesthetics, where he led the company through its initial public offering, led the international product launch for CoolSculpting and also served in corporate development; and director of finance at Proteolix, Inc., assisting in the sale of the company to Onyx Pharmaceuticals. He also held investment banking roles at Citigroup Global Markets, Inc. and Morgan Stanley. Over the course of his career, Mr. Brumm has raised approximately $1 billion in capital. In 2014, he was named Silicon Valley Business Journal’s CFO of the Year for companies under $500 million. He holds a B.A. in business administration from the University of Notre Dame.

About Dyne Therapeutics

Dyne Therapeutics is pioneering life-transforming therapies for patients with serious muscle diseases. The company’s FORCE™ platform delivers oligonucleotides and other molecules to skeletal, cardiac and smooth muscle with unprecedented precision to restore muscle health. Dyne is advancing treatments for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD). Dyne was founded in 2018 and is based in Waltham, Mass. For more information, please visit www.dyne-tx.com.

Media Contact

Ten Bridge Communications
Max Stendahl, 508-277-8117
max@tenbridgecommunications.com

Record changed: 2023-06-05